Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award - Priority Announcement: HIV Research (SHOPP)

University of Toronto

$8,750.00

Structural and functional characterization of HIV-1 viral infectivity factor (Vif): A novel axis for the design of anti-HIV drugs

EF 2011-12

Résumé
Once HIV enters its target cells in the human immune system, it releases its genetic material. In order for the virus to fully replicate in those immune cells, it needs to make a DNA copy of its genetic material. To prevent the generation of this DNA copy, the infected cells activate potent immune system enzymes termed the apolipoprotein B mRNA-editing catalytic polypeptide3 (APOBEC3) family of restriction factors. These enzymes cause aberrations in the viral genetic material, thereby inactivating the viral infection. However, fully-replicating HIV encodes for a protein termed viral infectivity factor (Vif). Vif binds to APOBEC3, targets it for degradation, and neutralizes the antiviral effect of APOBEC3. In our research, we propose to study the structure of HIV's viral infectivity factor (Vif); a protein discovered 20 years ago and currently believed by many researchers to be the most attractive target for the development of new anti-HIV drugs. The structural studies on this very difficult viral protein had been practically impossible, before I worked out the optimal conditions to prepare exceptionally high levels of soluble protein. Given my preliminary results, our lab is now in a strong position to study and fully describe the atomic-resolution structure of Vif. Vis's structure will give us, and the HIV research community worldwide, clues to the mechanistic action of Vif in general, and on APOBEC3 in particular. In addition, Vif's structure will provide a 'blueprint' for future design of new classes of HIV-1 therapeutics that can inactivate highly mutagenic HIV.
Programme
Master's Award - Priority Announcement: HIV Research (SHOPP)
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
258132
Name
Azimi Farshad
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Canadian Association for HIV Research (Ottawa)
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
Structural and functional characterization of HIV-1 viral infectivity factor (Vif): A novel axis for the design of anti-HIV drugs
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$8,750
Cihrequipment2
$0
Programname2
Master's Award - Priority Announcement: HIV Research (SHOPP)
Keyworddelim
Aids (Acquired Immunodeficiency Syndrome); Hiv (Human Immunodeficiency Virus); Nmr Spectroscopy; Protein Biochemistry; Protein-Protein Interaction; Surface Plasmon Resonance; Viral Infectivity Factor; X-Ray Crystallography
Abstract
Once HIV enters its target cells in the human immune system, it releases its genetic material. In order for the virus to fully replicate in those immune cells, it needs to make a DNA copy of its genetic material. To prevent the generation of this DNA copy, the infected cells activate potent immune system enzymes termed the apolipoprotein B mRNA-editing catalytic polypeptide3 (APOBEC3) family of restriction factors. These enzymes cause aberrations in the viral genetic material, thereby inactivating the viral infection. However, fully-replicating HIV encodes for a protein termed viral infectivity factor (Vif). Vif binds to APOBEC3, targets it for degradation, and neutralizes the antiviral effect of APOBEC3. In our research, we propose to study the structure of HIV's viral infectivity factor (Vif); a protein discovered 20 years ago and currently believed by many researchers to be the most attractive target for the development of new anti-HIV drugs. The structural studies on this very difficult viral protein had been practically impossible, before I worked out the optimal conditions to prepare exceptionally high levels of soluble protein. Given my preliminary results, our lab is now in a strong position to study and fully describe the atomic-resolution structure of Vif. Vis's structure will give us, and the HIV research community worldwide, clues to the mechanistic action of Vif in general, and on APOBEC3 in particular. In addition, Vif's structure will provide a 'blueprint' for future design of new classes of HIV-1 therapeutics that can inactivate highly mutagenic HIV.
Competitiondate
201202
Approvedterm2
1 yr 0 mth
Pinamesdelim
Azimi, Farshad
Approvedterm
1 an 0 mois
Cihrcontribution2
SPIR~ $8,750~ $0~